Mostrar el registro sencillo del ítem
Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.
dc.contributor.author | Vera, Ruth | |
dc.contributor.author | Gómez, María Luisa | |
dc.contributor.author | Ayuso, Juan Ramón | |
dc.contributor.author | Figueras, Joan | |
dc.contributor.author | García-Alfonso, Pilar | |
dc.contributor.author | Martínez, Virginia | |
dc.contributor.author | Lacasta, Adelaida | |
dc.contributor.author | Ruiz-Casado, Ana | |
dc.contributor.author | Safont, María José | |
dc.contributor.author | Aparicio, Jorge | |
dc.contributor.author | Campos, Juan Manuel | |
dc.contributor.author | Cámara, Juan Carlos | |
dc.contributor.author | Martín-Richard, Marta | |
dc.contributor.author | Montagut, Clara | |
dc.contributor.author | Pericay, Carles | |
dc.contributor.author | Vieitez, Jose María | |
dc.contributor.author | Falcó, Esther | |
dc.contributor.author | Jorge Fernández, Monica | |
dc.contributor.author | Marín, Miguel | |
dc.contributor.author | Salgado Fernández, Mercedes | |
dc.contributor.author | Viúdez, Antonio | |
dc.date.accessioned | 2022-03-23T08:56:10Z | |
dc.date.available | 2022-03-23T08:56:10Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32806731 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16387 | |
dc.description.abstract | Background: The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. Methods: Eligible patients were aged >/=18 years, with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and histologically-confirmed colon or rectal adenocarcinoma with measurable liver metastases. Preoperative treatment was bevacizumab (7.5 mg on day 1) + XELOX (oxaliplatin 130 mg/m(2), capecitabine 1000 mg/m(2) bid on days 1-14 q3w). After three cycles, response was evaluated by a multidisciplinary team. Patients who were progression-free and metastasectomy candidates received one cycle of XELOX before undergoing surgery 3-5 weeks later, followed by four cycles of bevacizumab + XELOX. Results: A total of 83 patients entered the study; 68 were eligible for RECIST, 67 for CTMC, and 51 for pathological response evaluation. Of these patients, 49% had a complete or partial RECIST response, 91% had an optimal or incomplete CTMC response, and 81% had a complete or major pathological response. CTMC response predicted 37 of 41 pathological responses versus 23 of 41 responses predicted using RECIST (p = 0.008). Kappa coefficients indicated a lack of correlation between the results of RECIST and morphological responses and between morphological and pathological response rates. Conclusion: CTMC may represent a better marker of pathological response to bevacizumab + XELOX than RECIST in patients with potentially-resectable CRC liver metastases. | en |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. | en |
dc.type | Journal Article | es |
dc.authorsophos | Vera, Ruth;Gómez, María Luisa;Ayuso, Juan Ramón;Figueras, Joan;García-Alfonso, Pilar;Martínez, Virginia;Lacasta, Adelaida;Ruiz-Casado, Ana;Safont, María José;Aparicio, Jorge;Campos, Juan Manuel;Cámara, Juan Carlos;Martín-Richard, Marta;Montagut, Clara;Pericay, Carles;Vieitez, Jose María;Falcó, Esther;Jorge, Mónica;Marín, Miguel;Salgado, Mercedes;Viúdez, Antonio | |
dc.identifier.doi | 10.3390/cancers12082259 | |
dc.identifier.pmid | 32806731 | |
dc.identifier.sophos | 36908 | |
dc.issue.number | 8 | es |
dc.journal.title | Cancers (Basel) | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médica | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | CHUO | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 12 | es |